Blueprint Medicines to Report Fourth Quarter and Full Year 2021 Financial Results on Wednesday, February 16, 2022

Rhea-AI Summary

Blueprint Medicines Corporation (NASDAQ: BPMC) is set to announce its fourth quarter and full year 2021 financial results on February 16, 2022, during a live conference call at 8:30 a.m. ET. The call will provide a comprehensive corporate update, detailing the company's performance. Investors can participate by calling 844-200-6205 or 929-526-1599, or via a webcast available on the company's website. Blueprint Medicines specializes in developing precision therapies targeting genetic drivers for cancer and blood disorders, with ongoing advancements across multiple therapeutic programs.

Positive

• Company will report financial results for Q4 and full year 2021, indicating potential growth insights.
• Ongoing advancements in precision therapies for cancer and blood disorders may enhance market position.

Negative

• None.

CAMBRIDGE, Mass., Feb. 9, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, February 16, 2022 to report its fourth quarter and full year 2021 financial results and provide a corporate update.

To access the live conference call, please dial 844-200-6205 (domestic) or 929-526-1599 (international), and refer to conference ID 936793. A webcast of the call will also be available under "Events and Presentations" in the Investors & Media section of the Blueprint Medicines website at http://ir.blueprintmedicines.com/. The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call and will be available for 30 days following the call.

About Blueprint Medicines

Blueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and blood disorders. Applying an approach that is both precise and agile, we create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Today, we are delivering approved medicines directly to patients in the United States and Europe, and we are globally advancing multiple programs for systemic mastocytosis, lung cancer and other genomically defined cancers, and cancer immunotherapy. For more information, visit www.BlueprintMedicines.com and follow us on Twitter (@BlueprintMeds) and LinkedIn.

View original content to download multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-to-report-fourth-quarter-and-full-year-2021-financial-results-on-wednesday-february-16-2022-301477978.html

SOURCE Blueprint Medicines Corporation

FAQ

When will Blueprint Medicines report its financial results?

Blueprint Medicines will report its financial results on February 16, 2022.

What time is the conference call for the financial results?

The conference call will be held at 8:30 a.m. ET on February 16, 2022.

How can I access the live conference call for Blueprint Medicines?

You can access the live conference call by calling 844-200-6205 (domestic) or 929-526-1599 (international) using conference ID 936793.

Where can I find the archived webcast for Blueprint Medicines' financial results?

The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call.